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Abstract
Background—High-volume (HV) center surgery and gynecologic oncology care are associated 
with improved outcomes for women with uterine cancer. Referral patterns, from biopsy through to 
chemotherapy, may have patients interacting with HV centers for all, a portion, or none of their 
care. The relative frequency, the underlying factors that contribute to referral, and the potential 
impact of these referral patterns on treatment outcomes are unknown.
Objective—To analyze the referral patterns and subsequent impact of care sites on treatment for 
women with high and low risk uterine cancer.
Methods—This is a population-based retrospective cohort study of uterine cancer cases from 
2004–09 in North Carolina. Using state cancer registry files linked to Medicare, Medicaid, and 
private payer insurance claims, we analyzed referral and treatment patterns by annual surgical 
volume (High ≥ 12/year). We examined clinical and demographic factors associated with referral 
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and used modified Poisson regression to evaluate risk of referral, lymphadenectomy and 
chemotherapy. Stratified Kaplan Meier plots and Cox proportional hazard models were used to 
examine survival.
Results—A total of 2,053 women were analyzed, including 34% (n=677) with Grade 3 histology. 
Of 1,630 (80%) of women with pre-operative biopsies, referral patterns (Biopsy to Surgery) were: 
LV to HV (n=652, 40%), followed by HV to HV (n=605, 37%), then LV to LV (n=318, 20%), and 
the rare HV to LV (n=50, 3%). Women retained in Low-Volume centers after biopsy were older, 
were less likely to have private insurance, and had more comorbidities. High-risk histology (aRR 
1.14, 95%CI: 1.04–1.25) was positively associated with referral, while Medicaid insurance was 
negatively associated with referral (aRR 0.64, 95%CI: 0.42–0.96). Most women (74%, n=1,557) 
had surgery at HV centers. Lymphadenectomy was less likely at Low-Volume (LV) centers (aRR 
0.71, 95%CI: 0.64–0.77). Similarly, for high-risk patients, the relationship between LV center 
surgery and subsequent chemotherapy was aRR 0.71 (95%CI: 0.48–1.02).
Of 290 women who received chemotherapy, the referral patterns (Surgery to Chemotherapy) were: 
HV- All (HV to HV), HV-Hybrid (HV to LV, or LV to HV), and HV-None (LV to LV). 36% 
(n=104/290) received chemotherapy at a LV center, the majority (68%, n=71/104) of whom were 
referred from out of HV centers after surgery. Crude, unadjusted mortality risk of chemotherapy 
recipients differed by referral pattern (Surgery to Chemotherapy): HV-All patients (HR 1.0, 
referent), followed by HV-Hybrid (HR 1.33, 95%CI: 0.93–1.91) then HV-None patients (RR 1.95, 
95%CI:1.24–3.08).
Conclusion—Most women with uterine cancer treated at High-Volume centers arrive through 
referral, which is affected by age and type of insurance, in addition to histology. For high-risk 
women who require chemotherapy, survival may be related to the extent of treatment received at 
High-Volume centers.
Keywords
Uterine cancer; treatment patterns; high volume; outcomes
Introduction
The majority of uterine cancer patients undergo surgery by general gynecologists,1–3 despite 
documented benefits of gynecologic oncology treatment. Women most likely to benefit from 
a gynecologic oncologist are older women (age > 70) and women with high-risk histology 
(grade 3 and/or non-endometrioid).3 In addition, gynecologic oncology training is highly 
correlated with high annual surgical volume, which in turn, has been associated with 
improved perioperative outcomes in uterine cancer patients1.
Despite this data, the frequency with which women with uterine cancer are referred to high-
volume centers is unclear. To our knowledge, all studies assessing surgical volume in uterine 
cancer have focused on the single surgical episode.1,2,4–6 This excludes information on the 
referral patterns both before and after surgery. One critical transition point in uterine cancer 
care is the step from diagnostic biopsy to receipt of surgery. Women may be initially 
diagnosed at High-Volume centers and remain there for surgery. On the other hand, perhaps 
more often, they may be initially diagnosed in a primary care, Low-Volume setting, and then 
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subsequently referred to a High-Volume center. Another critical transition point, for high-
risk patients, is from surgery to chemotherapy. For patients with high-risk histology, it is 
especially important to understand these referral patterns. They experience higher mortality 
and often require adjuvant chemotherapy for the best chance of cure.7–1011
There is no evidence describing the proportion of uterine cancer patients who follow the 
different referral patterns, the influence of histology, demographics, or other factors on these 
patterns, nor their impact on clinical outcomes.
The goal of this study was to examine these questions at a population level, including 
women of all ages, enrolled in Medicare, Medicaid, and privately insured health plans. 
Specifically, we sought to (1) describe the relative frequency and demographic features of 
women in each referral pattern, and (2) analyze the association of demographic and clinical 
factors with likelihood of referral and subsequent treatment and outcomes.
Methods
Data Source and Study Population
This study was approved by the North Carolina Institutional Review Board (# 13-2863). The 
North Carolina Central Cancer Registry (NCCCR), a state-level mandatory reporting 
registry, was used to identify all women in North Carolina diagnosed with a primary uterine 
cancer, from January 1st 2004–June 30th 2009. Women who were diagnosed at death or 
autopsy, had a prior cancer diagnosis, or a major primary disability were excluded using 
NCCCR flags and International Classification of Disease (ICD)-O-3 site and morphology 
codes. The North Carolina Integrated Cancer Information and Surveillance System (ICISS) 
links identified cancer cases from the NCCCR with administrative data from Medicare, 
Medicaid and beneficiaries in privately insured health plans across the state.11 Over 80% of 
the unique cancer registry patients link to at least one of the administrative databases 
captured in the ICISS data. The NC Cancer Registry is a “gold certified” registry based on 
the North American Association of Central Cancer Registries (NAACCR) standards and 
includes 99% valid, complete social security numbers, as well as other key identifiers such 
as first, maiden, and last names, date of birth, and address. The Medicare and Medicaid 
beneficiaries are linked to the registry via the Center for Medicare and Medicaid Services 
(CMS) contractor General Dynamics using a deterministic, exact match on social security 
numbers. The privately insured beneficiaries are linked through both deterministic 
(SEER141 Medicare algorithm) and probabilistic algorithm incorporating Bayes formula 
which results in a linkage of 100% sensitivity, 98% specificity and a 95% Positive Predictive 
Value (PPV).11 Due to administrative lag in data availability, the Medicaid enrollment file 
extends to 2008, while all other enrollment data is through 2009. We restricted the sample to 
women with linked, continuous enrollment, in any payer, from 6 months prior to 6 months 
after diagnosis date. This allowed for accurate capture of comorbidity, diagnosis, and 
treatment data. Due to small numbers, women with missing or unknown race/ethnicity 
information were excluded.
Tumor histology and morphology codes were grouped into the following categories: 
endometrioid adenocarcinoma, serous carcinoma, carcinosarcoma, sarcoma, and other 
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(Supplemental Table A.1). High-risk histology was defined as Grade 3 – 4 and/or any non-
endometrioid histology. Grade 3 (poorly differentiated) and 4 (undifferentiated) were 
combined into one category of Grade 3 as this reflects how they are defined and treated 
clinically. For the purposes of assessing frequency of chemotherapy delivery, the population 
denominator was restricted to non-endometrioid histology, as this group is uniformly 
recommended to have chemotherapy by national guidelines.10
Exposure and Outcome Variables
Histology type and treatment sites were the primary exposure variables. Treatment sites 
were identified using zip codes on provider billing claims for each episode of care (biopsy, 
surgery, chemotherapy). The zip codes were then categorized into High-Volume centers 
based on uterine cancer hysterectomy volume (≥ 60 cases) during the 5 year study period. In 
addition, the presence of a gynecologic oncology specialist practicing at that location as 
determined from the Society of Gynecologic Oncology membership database was 
determined. There was high concordance (89%) between these 2 criteria, and case volume 
was used first to define the HV and LV groups. The numerical cut-off for surgical volume 
was consistent with prior studies,1,3,5 using cut-offs ranging from 10–14.5 mean cases/year. 
Zip codes that identified outreach practice locations of known gynecologic oncologists were 
classified with the High-Volume center of the gynecologic oncologist’s primary practice 
location (n=6). The 4 potential referral patterns included High-Volume biopsy to High-
Volume Surgery (HV-HV), High-Volume Biopsy to Low-Volume Surgery (HV-LV), Low-
Volume Biopsy to High-Volume Surgery (LV-HV), and Low-Volume Biopsy to Low-Volume 
Surgery (LV-LV). Volume status, at each point of care (biopsy, surgery, chemotherapy) was 
therefore based on uterine cancer hysterectomy volume of that zip code. For example, a 
biopsy done by a general gynecologist at a tertiary center that had high uterine cancer 
hysterectomy volume, would be classified as a “HV” biopsy.
Primary study outcomes were referral pattern, performance of lymphadenectomy, and 
chemotherapy administration for high-risk histology. Exploratory analysis of all-cause 
mortality was also performed. Hysterectomy was defined using Common Procedure 
Terminology (CPT) codes for hysterectomy, occurring at the time of or after cancer 
diagnosis (Supplemental Table A.1). Lymphadenectomy was defined using the nodal staging 
information from the cancer registry, which specifies whether or not lymph nodes were 
removed. Chemotherapy administration was defined by the presence of ICD9 administration 
or Healthcare Common Procedure Coding System (HCPCS) medication codes in the claims, 
using an algorithm validated in many cancer types, including ovarian.12 Mortality 
information came from the state cancer registry, updated through 2014.
Covariates
Covariates included age, race/ethnicity, population density of residence county, stage at 
diagnosis, comorbidity, and insurance payer. Age at diagnosis and race/ethnicity were 
reported from the NCCCR. Due to small sample size with granular race and ethnicity 
categories, all non-White, Non-Hispanic categories were grouped into “Racial and Ethnic 
minorities”. Stage at diagnosis was reported with the summary staging variable (local, 
regional, distant, unknown) common to state and national cancer registries, and broadly 
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corresponds to FIGO Stage 1 (local), Stage 2–3 (regional), and Stage 4 (distant) 
categorization.13,14 There were no changes in staging classification during the study period. 
Rural/urban classification from the United States Department of Agriculture was 
dichotomized at the county level into Metro vs. Non-metro based on Rural/Urban 
Continuum codes from 2013.15 Comorbidity was assessed using methods reported by Gagne 
et al,16 which incorporates both the Charlson comorbidity index and the Elixhauser 
comorbidity score, to provide the most comprehensive assessment of health status. Data 
from outpatient and inpatient clinical settings is incorporated into the scoring system. Those 
with scores ≥ 1 represent patients with a comorbidity profile that is associated with greater 
hospitalization and health care utilization and/or greater mortality risk. In this scale 
comorbidity values can be < 0 for conditions actually associated with decreased health care 
use. This group was nearly identical to those with scores of 0, and therefore comorbidity was 
dichotomized into ≤0 vs ≥1. For multivariate analysis, insurance payers were grouped into 3 
mutually exclusive categories of any private payer, Medicare only, or any Medicaid.
Statistical Analysis
We performed univariate and bivariate analysis of histology type, the covariates and the 
primary outcomes of referral pattern, lymphadenectomy, and chemotherapy receipt. Chi 
square statistic, student’s t-test, and analysis of variance (ANOVA) tests were used to assess 
the relationships between independent variables and outcome variables. We constructed 
multivariable models using modified Poisson regression to generate risk ratios of referral 
pattern, lymphadenectomy, and chemotherapy receipt. Survival was explored by generating 
Kaplan Meier curves stratified by care model type and Cox proportional hazard models to 
generate crude hazard ratios (HR) for time to death (mortality). Statistical significance was 
set at p<0.05. Analysis was performed using SAS v9.3 (Cary, NC).
Results
Study Population and Sites of Care
A total of 6,180 women were diagnosed with uterine cancer in North Carolina from January 
1st 2004 – June 30th 2009. Of these, 1,393 (23%) were excluded for: diagnosis at autopsy 
(n=37), prior cancer diagnosis (n=771), and primary disability (n=588). Of the remaining 
4,784 women, 2,461 had linked, continuous enrollment in one of the three payers for at least 
6 months prior to 6 months after diagnosis. After further exclusions at the claims level, 
2,053 women comprised the cohort (Figure 1).
Twenty-four sites of care were identified and grouped into 18 distinct practices. Half (9/18) 
were identified as High-Volume centers and half as Low-Volume centers. Most patients had 
surgery at High-Volume centers (n=1,557 [74%]). Low-Volume centers had more patients 
who were in the tails of the age distribution (20–49 and 75+), who resided in non-metro 
counties, who had public insurance, and who had higher comorbidity scores (Table 1).
Referral Patterns: Biopsy to Surgery
Eighty percent (n=1,630) of women had documented pre-operative endometrial biopsy. 
Overall, 60% (970/1,630) of patients were initially biopsied at a Low-Volume center and 
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40% (660/1630) at a High-Volume center. The most common pattern of referral, from biopsy 
to surgery, was the Hybrid model (LV-HV [n=652, 40%]), followed by all High-Volume care 
(HV-HV [n=605,37%]), and then by all Low-Volume care (LV-LV [n=318,21%]). The 
remaining 55 women were in the rare HV-LV pattern (3%). We suspect this unusual pattern 
may be the result of women diagnosed outside of their usual care pattern, such as a biopsy in 
the emergency department or during travel. These women are likely to subsequently follow 
up with their usual care primary providers. The 3 main referral groups differed 
demographically by age, county of residence, insurance type, and comorbidity. As a group, 
women in the LV-LV pattern were older, resided in more non-metro counties, had less 
private insurance, and higher comorbidity scores (Table 2).
In the multivariate analysis, for all women initially biopsied in a Low-Volume center, we 
assessed the likelihood of referral to a High-Volume center. Women with high-risk histology 
(RR 1.14 [95% CI:1.04–1.25]) were more likely to be referred to a High-Volume center to a 
small degree, while women with Medicaid insurance were less likely to be referred (RR 0.64 
[95% CI:0.42–0.96]) (Table 3).
Treatment Patterns at the time of Surgery
The overall rate of lymphadenectomy totaled 67%. On bivariate analysis, lymphadenectomy 
was significantly more common when surgery was performed at High-Volume centers (74% 
vs 46%, p<0.001). Lymphadenectomy was also more common among those with high-risk 
histology (74% vs 69%, p=0.041). In multivariate models, which included adjustment for 
histologic grade, women treated at Low-Volume centers remained less likely to undergo 
lymphadenectomy (RR 0.71, 95% CI 0.65–0.78) (Supplemental Table A.2).
For women with non-endometrioid histology, the overall rate of chemotherapy receipt was 
38.9% (n=151/385). After surgery at a High-Volume center, 41% (n=123/297) of women 
with non-endometrioid histology received chemotherapy. In contrast, after surgery at a Low-
Volume center, only 31% (n=28/88) of women with non-endometrioid histology received 
chemotherapy (p=0.105). After adjusting for covariates, the association between Low-
Volume center surgery and receipt of chemotherapy was aRR 0.71 (95% CI: 0.49–1.03) 
(Supplemental Table A.3).
Referral patterns: Surgery to Chemotherapy
For all patients who received chemotherapy, the site of surgery and site of chemotherapy 
were used to create 3 referral care model groups: High-Volume-All (HV-All), High-Volume-
Hybrid (HV-Hybrid), and High-Volume-None (HV-None) (Table 4). Most, 65%, were in 
HV-All, 25% were in HV-Hybrid, and 11.5% of patients where in HV-None referral care 
models. There were significant demographic and treatment differences between the referral 
groups. Both HV-None and HV-Hybrid referral groups had more patients with public 
insurance and with ≥ 1 comorbidity compared to the HV-All group. Both HV-None and HV-
Hybrid also had fewer patients with local stage disease. HV-None had more with unknown/
missing stage, and HV-Hybrid had more with regional stages.
Both HV-Hybrid and HV-None patients had lower survival probabilities than HV-All 
patients (Figure 2). In a crude, unadjusted model of mortality risk, HV-None was associated 
DOLL et al. Page 6
Am J Obstet Gynecol. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
with the greatest mortality risk (HR 1.95, 95%CI: 1.24 – 3.08), followed by HV-Hybrid (HR 
1.33, 95%CI: 0.93 – 1.91), although the latter was not statistically significant.
Comment
To our knowledge, this is first study to evaluate population-level referral patterns for uterine 
cancer, from biopsy through to chemotherapy, based on histologic risk. Our ability to follow 
both publically and privately insured patients, of all ages, through multiple sites of care 
delivery is unique and lends generalizability to our data. When all steps of care are 
considered, nearly half of uterine cancer patients are in hybrid referral patterns that 
incorporate both High-Volume and Low-Volume centers. For each critical transition point, 
there were differences in treatment based on referral pattern. Although high-risk histology 
did modestly increase the likelihood of referral to a High-Volume center for surgery, these 
high-risk types still comprised a third of women treated at Low-Volume centers, where 
likelihood of lymphadenectomy was significantly lower. A third of patients requiring 
chemotherapy received it at Low-Volume centers, the majority of whom were actually 
referred from out of High Volume centers after their surgery. These patients, in Hybrid care 
models, had survival outcomes better than those with no care at High Volume centers, but 
worse than those with all care at High Volume centers.
Women with high-risk uterine cancer should not receive surgical care at Low-Volume 
centers.7,8,15 In comparison to the more common, low-risk histology, Grade 3 endometrioid 
tumors and all non-endometrioid tumors are aggressive uterine cancers that have higher 
recurrence and substantially decreased survival.9 The vast majority of women in our sample 
had endometrial biopsies before definitive surgery, allowing opportunity for appropriate 
referral. In our analysis however, although tumor biology was a factor, insurance type was 
also strongly associated with referral patterns to High-Volume centers. In addition, older age 
and increased comorbidity characterized the population of women who were never seen at 
High-Volume centers. These vulnerable patients may be the ones who could most benefit 
from the extended multi-disciplinary services usually available at High-Volume centers. 
Because endometrial biopsies are often performed in primary care settings, general 
gynecologists and other women’s health care providers serve as crucial gatekeepers to the 
initiation of quality uterine cancer care.
Referral to a High-Volume center makes a difference in the type of care received. In our 
study, patients who had surgery at High-Volume centers were more likely to undergo 
lymphadenectomy. A greater proportion of these women also received subsequent 
chemotherapy if they had high-risk histology. This is consistent with previous studies 
associating gynecologic oncology care with increased number of lymph nodes removed and 
chemotherapy administration.2 Case volume studies in uterine cancer have focused on 
perioperative morbidity and mortality outcomes. Wright et al reported on bivariate analysis 
that lymphadenectomy was associated with increasing laparoscopic, but not abdominal 
hysterectomy volume for endometrial cancer.4,5 To our knowledge this is the first study to 
relate hysterectomy surgical volume to lymphadenectomy and chemotherapy administration 
in a multivariate analysis. Our results suggest that the quality of care received goes beyond 
the surgical episode.
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We did note the seemingly low (41%) chemotherapy administration rate among non-
endometrioid histology cases in our study. We hypothesize that this is mainly due to 2 
factors: 1) the dates of study (2004 – 2009) correspond to the emerging literature on the 
benefits of chemotherapy in early-stage non-endometrioid uterine cancers17–22 and 2) 
guideline adherent care is usually less common than is perceived. For example, the 2013 
statewide study by Bristow et al on ovarian cancer treatment patterns demonstrated that only 
37% of patients received guideline adherent care, including only 50.8% at high-volume 
hospitals.23 Low rates of chemotherapy have also been observed and validated in other 
population-based studies of cancer including >30% of stage 3 colon patients who do not 
receive adjuvant chemotherapy despite clear recommendations.24
For uterine cancer patients requiring chemotherapy, Hybrid referral care models were 
common. Specifically, the phenomenon of a patient being referred from a Low-Volume area 
to a High-Volume center for surgery, then moving back to a Low-Volume area for adjuvant 
chemotherapy occurred in nearly 25% of patients. These patients tended to be those without 
private insurance, with higher comorbidity, and with later stage disease. These are all risk 
factors for poor outcomes and may represent the very patients with the most to gain from 
staying in a High-volume center for adjuvant treatment. Our results are preliminary. This 
was this was a crude regression model, unadjusted for covariates, as we did not have the 
sample size for a robust multivariate survival analysis. It is important, however, for 
gynecologic oncology providers to realize that after completing a patient’s initial surgery, 
post-operative referral for adjuvant chemotherapy may not result in the same quality of care 
as patients who are retained at High-Volume centers.
Our study addresses some of the factors associated with referral patterns to HV centers, but 
not all. Geography, in particular, may be a strong factor in referral. In studies of ovarian and 
endometrial cancer patients, those who live greater than 20 – 50 miles from HV centers are 
less likely to be treated at HV centers.5,25 In addition, we imagine that those patients who 
can overcome the travel distance may be willing to do so for an isolated treatment, like 
surgery, but not for ongoing care, as in the case of chemotherapy. However, rural patients are 
more willing to travel further distances for care26,27 and racial/ethnic minorities are more 
likely to live in close proximity to gynecologic oncologists.28 As such, it is critical to 
understand who stands to benefit the most from continued HV center care, to both invest 
resources to support continued travel for high-risk patients, while avoiding unnecessary 
travel burden for low-risk patients.
Our study has several limitations, many of which are consistent with registry-linked claims 
data29. First, we are limited to a single state, so our results may not be generalizable 
nationwide, although rates of uterine cancer in North Carolina are similar to SEER reports. 
Second, due to the inherent instability of Medicaid coverage,30 the majority of the Medicaid 
population had to be excluded due to a lack of 12 months of continuous claims. This limited 
our racial/ethnic minority population and significantly affected our ability to identify 
disparities in this group. Third, the comorbidity assessment incorporates both inpatient and 
outpatient information from Charleson and Elixhauser scoring systems, but still may 
underestimate comorbidities. Fourth, as we do not have specific medical record information, 
we do not know how many patients were actually referred by providers, but for other reasons 
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did not go to High-Volume centers. In addition, our definition of ‘referral’ is based on 
movement between zip codes, and not specific provider changes, which allows for a patient 
who undergoes biopsy and surgery by the same provider to be classified as a HV to HV or 
LV to LV ‘referral,’ rather than a non-referral. Fifth, we could not account for the possibility 
of discrepant histology results from biopsy compared to surgery. The literature suggests that 
among grade 1–2 biopsy results, upstaging to a grade 3 pathology occurs approximately 8% 
of the time31 which represents a small potential fraction of all patients. Finally, since our 
data were derived based on specific insurance enrollment, we were unable to include data 
from cancer patients who had interrupted coverage, who were covered on smaller private 
plans not included in our dataset, or who never had any insurance coverage during the study 
period. In North Carolina, the uninsured rates for ages 18 – 64 is at 22.5%32.
Overall, our study supports that with regard to the care of women with uterine cancer, 
referral patterns matter in treatment delivery and, possibly, survival. This is a cancer where 
the majority of diagnostic biopsies occur in the primary care or general gynecologists’ 
office. These providers are the gatekeepers for appropriate referral of high-risk patients for 
High-Volume specialty treatment. The centralization of cancer treatment should be patient-
centered and risk-based. It is not all or none. Further work to elucidate the provider-level 
factors that lead to these referral patterns will be important in designing systematic 
interventions to align high-risk patients with appropriate, specialty care to improve patient 
outcomes.
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Figure 1. Study Population
Detail of exclusions at the state registry and claims level.
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Figure 2. Kaplan-Meier Survival Curves by Referral Care Model in All Chemotherapy Patients
Crude survival probabilities, starting from 6 months after diagnosis, for all patients who 
received chemotherapy after surgery, stratified by HV referral care model type. HV-All: 
Surgery and chemotherapy received at HV centers. HV-Hybrid: Surgery at HV center, 
Chemotherapy at LV center. HV469 None: Surgery and chemotherapy at LV center.
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Table 1
Cohort Characteristics of Patients with Uterine Cancer Who Underwent Surgery at High and Low Volume 
Centers in North Carolina, 2004–09a
Characteristic All N = 2053 High Volume n = 1557 Low Volume n = 496 P
Age (y)b 66.5±12 66.2± 12 67.2± 13 0.106
 20 – 49 172(8) 123(8) 49(10)
 50 – 64 609(30) 492(32) 117(24)
 65 – 75 732(36) 546(35) 186(38)
 > 75 540(26) 396(25) 144(29) 0.006
Race and Ethnicity
 White, Non-Hispanic 1,714(83) 1,308(84) 412(83)
 Racial/Ethnic Minority 339(17) 255(16) 84(17) 0.771
Population Density of Residence County
 Metroc >1,368(67) >1,082(69) >286(58)
 Non-Metro 664(32) 464(30) 200(40)
 Missingc ≤ 20 ≤10 ≤10 <.001
Insurance Payer
 Medicare Only 1,096(53) 798(52) 298(60)
 Private 896(43) 718(46) 174(35)
 Medicaid 65(3) 41(3) 24(5) <.001
Year of Diagnosis
 2004 337(16) 234(15) 103(21)
 2005 371(18) 247(16) 124(25)
 2006 339(17) 255(16) 84(17)
 2007 363(18) 289(19) 74(15)
 2008 417(20) 339(22) 78(16)
 2009 226(11) 193(12) 33(7) <.001
Summary Stage
 Local 1,513(74) 1,143(73) 370(75)
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Characteristic All N = 2053 High Volume n = 1557 Low Volume n = 496 P
 Regional 399(19) 306(20) 93(19)
 Distant 111(5) 92(6) 19(4)
 Missing/Unknownc ≤ 20 ≤10 ≥10 .009
Grade
 1 793(39) 596(38) 197(40)
 2 551(27) 421(27) 130(26)
 3 592(29) 478(31) 114(23)
 Unknown 117(6) 62(4) 55(11) <.001
Histology
 Low-Risk 1,342(65) 999(64) 343(69)
 High-Risk 711(35) 558(36) 153(31) 0.042
Comorbidity
 0 1585 (77) 1219(78) 366(74)
 ≥ 1 468(23) 338(22) 130(26) .037
Biopsy before Surgery
 No 418 (20) 295 (19) 123 (25)
 Yes 1635 (80) 1,262 (81) 373 (75) .005
a
Information presented as No. (%) except where noted.
b
Presented as mean ± standard deviation
cValues surppresed due to small cell size, as pursuant to the data use agreement
d
High-risk includeds Grade 3 and any Non-Endometrioid histology
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Table 3
Likelihood of Referral to a High-Volume Center following Initial Biopsy at a Low-Volume Center, Modified 
Poisson Regression
Factor aRR 95%CI
Age (by 1 yr) 1.00 0.99–1.00
Diagnosis Year
 2004 Referent
 2005 0.82a 0.67 – 1.00
 2006 1.12 0.95 – 1.32
 2007 1.23b 1.05 – 1.43
 2008 1.17a 1.00 – 1.36
 2009 1.23a 1.04 – 1.45
Race
 White, NH Referent
 Racial/Ethnic Minority 0.98 0.87 – 1.10
Population Density
 Metro Referent
 Non-Metro 0.99 0.90 – 1.07
Insurance
 Any Private Referent
 Medicare Only 0.92 0.81 – 1.03
 Any Medicaid 0.64a 0.42 – 0.96
Comorbidity
 ≤0 Referent
 ≥1 0.98 0.87 – 1.09
Histology
 Low-Risk Referent
 High-Risk 1.14b 1.04 – 1.25
ap<.05,
bp<.01
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